Novartis receives FDA Breakthrough Therapy designations for STAMP inhibitor asciminib (ABL001)
ABL-001 – A Branded Store
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1 | Nature
A, Selectivity profiles of GNF-2, GNF-5, and ABL-001 in contrast to two... | Download Scientific Diagram
Details of the molecular interactions between GNF-2 and ABL001 and the... | Download Scientific Diagram
GME Antenna Base Universal with 4.5m Coaxial & PL259 - ABL001 - Accessories | Repco New Zealand
ABL Bio
BCR-ABL inhibitor asciminib (ABL001) meets phase 3 primary endpoint in CML | BLU Ampersand, Inc.
Dual Drug Targeting of Mutant Bcr‐Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance - El Rashedy - 2018 - Chemistry & Biodiversity - Wiley Online Library
ABL 001, Asciminib | New Drug Approvals
Molecules | Free Full-Text | Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to
ABL-001-Amide-PEG3-acid | Fluorescent Probe | MedChemExpress
eMolecules ABL-001 | 1492952-76-7 | | 5mg, Quantity: Each of 1 | Fisher Scientific
Asciminib | C20H18ClF2N5O3 | CID 72165228 - PubChem
ABL Bio
Asciminib (ABL001) | 99.88%(HPLC) | In Stock | Bcr-Abl inhibitor
ABL 001, Asciminib | New Drug Approvals
ABL-001 XLR Male Connector, 2 A, Stainless Steel
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1 | Nature
![PDF] Allosteric Inhibition of ABL Kinases: Therapeutic Potential in Cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/b853a68006d343df3e92d114b15061d3842b2ba4/3-Figure2-1.png "PDF] Allosteric Inhibition of ABL Kinases: Therapeutic Potential in Cancer | Semantic Scholar")
PDF] Allosteric Inhibition of ABL Kinases: Therapeutic Potential in Cancer | Semantic Scholar
ABL-001 | 1492952-76-7
Efficacy of a combination of TKI and a novel allosteric inhibitor asciminib in chronic myeloid leukaemia | Faculty of Sciences, Engineering and Technology | University of Adelaide
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1 | Nature
